GSK3B and non-small cell lung carcinoma: To illustrate, cisplatin-resistant non-small cell lung cancer (NSCLC) cell line showed upregulation of β-catenin due to phosphorylation-dependent inhibition of GSK3β [42], and cisplatin-resistant hepatocellular carcinoma cells exhibited nuclear accumulation of GSK3β [43].